公开(公告)号：US07740877B2

公开(公告)日：2010-06-22

申请号：US11784528

申请日：2007-04-06

Applicant: Sung Wan Kim ,  Seongbong Jo ,  Jin Kim

Inventor： Sung Wan Kim ,  Seongbong Jo ,  Jin Kim

IPC: A61F2/02 ,  C08G63/08

CPC classification number: C08L67/04 ,  A61K9/0024 ,  A61K9/06 ,  A61K47/34 ,  C08G63/664

Abstract: A thermogelling, aliphatically modified polymer for use in drug delivery is described. Illustrative embodiments include poly(lactic-co-ε-caprolactone)-poly(ethylene glycol)-poly(lactic-co-ε-caprolactone) hexanoate and poly(lactic-co-ε-caprolactone)-poly(ethylene glycol)-poly(lactic-co-ε-caprolactone) laurate. Another illustrative embodiment includes a composition having a thermogelling amount of an aliphatically modified poly(lactic-co-ε-caprolactone)-poly(ethylene glycol)-poly(lactic-co-ε-caprolactone) and an effective amount of a drug. The thermogelling polymers are made by bonding an aliphatic group to poly(lactic-co-ε-caprolactone)-poly(ethylene glycol)-poly(lactic-co-ε-caprolactone). A method of use includes injecting a warm-blooded individual with a thermogelling amount of the aliphatically modified polymer and a drug.

Abstract translation: 描述了用于药物递送的耐热凝胶，脂质改性聚合物。 说明性实施方案包括聚（乳酸 - 共 - 己内酯） - 聚（乙二醇） - 聚（乳酸 - 共 - 己内酯）己酸酯和聚（乳酸 - 共 - 己内酯） - 聚（乙二醇 ） - 聚（乳酸 - 共 - 己内酯）月桂酸酯。 另一个说明性实施方案包括具有热凝胶量的脂族改性聚（乳酸 - 共 - 己内酯） - 聚（乙二醇） - 聚（乳酸 - 共 - 己内酯）和有效量的药物 。 热胶凝聚合物通过将脂族基团与聚（乳酸 - 共 - 己内酯） - 聚（乙二醇） - 聚（乳酸 - 共 - 己内酯）结合而制备。 一种使用方法包括用热胶凝量的脂质改性聚合物和药物注射温血个体。

公开(公告)号：US20100010067A1

公开(公告)日：2010-01-14

申请号：US12496568

申请日：2009-07-01

Applicant: Sun Hwa Kim ,  Ji Hoon Jeong ,  Tae-il Kim ,  Sung Wan Kim ,  David A. Bull

Inventor： Sun Hwa Kim ,  Ji Hoon Jeong ,  Tae-il Kim ,  Sung Wan Kim ,  David A. Bull

IPC: A61K48/00 ,  C08G75/14 ,  C12N15/09

CPC classification number: A61K9/5146 ,  A61K47/34 ,  A61K47/59 ,  A61K47/595 ,  A61K47/6455 ,  A61K48/0041 ,  C12N15/111 ,  C12N2320/32

Abstract: An arginine-grafted bioreducible poly(disulfide amine) (“ABP”) as a reagent for efficient and nontoxic gene delivery is described. ABP forms positively charged nano-particles of less than 200 nm with siRNA. ABP is biodegraded under reducing conditions, such as in the cytoplasm. ABP exhibits much higher transfection efficiency than polyethyleneimine in mammalian cells and exhibits no cytotoxicity. ABP is an effective delivery vehicle for gene silencing with siRNA and may be used for treating cancer.

Abstract translation: 描述了精氨酸接枝的可生物还原的聚（二硫化胺）（“ABP”）作为有效和无毒的基因递送的试剂。 ABP用siRNA形成小于200nm的带正电荷的纳米颗粒。 ABP在还原条件下如细胞质中生物降解。 与哺乳动物细胞中的聚乙烯亚胺相比，ABP的转染效率高得多，不显示细胞毒性。 ABP是用于siRNA基因沉默的有效递送载体，可用于治疗癌症。

公开(公告)号：US20090130752A1

公开(公告)日：2009-05-21

申请号：US12267015

申请日：2008-11-07

Applicant: Sung Wan Kim ,  Mei Ou

Inventor： Sung Wan Kim ,  Mei Ou

IPC: C12N15/00 ,  C07C233/00 ,  C07H21/00 ,  C12N15/63 ,  C07H21/02

CPC classification number: C07C323/41 ,  C07H21/00 ,  C07H21/02 ,  C12N15/87

Abstract: Poly(disulfide amine)s, methods of making, and methods of use are described. Illustrative embodiments of the poly(disulfide amine)s include poly(CBA-DAE), poly(CBA-DAB), and poly(CBA-DAH). These compositions are made by Michael addition between N,N′-cystaminebisacrylamide and N-Boc-protected diamine monomers, followed by N-Boc deprotection. Complexes are formed by mixing the poly(disulfide amine)s with nucleic acid. Delivery of the nucleic acid into cells is carried out by contacting the cells with the nucleic acid/poly(disulfide amine) complexes.

Abstract translation: 描述了聚（二硫化物胺），制备方法和使用方法。 聚（二硫化物胺）的说明性实施方案包括聚（CBA-DAE），聚（CBA-DAB）和聚（CBA-DAH）。 这些组合物是通过在N，N-半胱氨酸二亚甲基丙烯酰胺和N-Boc-保护的二胺单体之间加入Michael，然后进行N-Boc去保护来制备的。 通过将聚（二硫化物胺）与核酸混合形成络合物。 通过使细胞与核酸/聚（二硫化物胺）络合物接触来进行将细胞递送到细胞中。

公开(公告)号：US5853723A

公开(公告)日：1998-12-29

申请号：US710653

申请日：1996-09-20

Applicant: Harvey Jacobs ,  Sung Wan Kim ,  Virginie Menard

Inventor： Harvey Jacobs ,  Sung Wan Kim ,  Virginie Menard

IPC: A61K39/395 ,  A61K31/00 ,  A61K38/00 ,  A61K39/44 ,  A61K47/48 ,  A61P3/00 ,  A61P3/10 ,  C07K16/40 ,  A61K47/00

CPC classification number: A61K47/48215 ,  A61K39/44 ,  A61K47/48646 ,  C07K16/40 ,  A61K38/00 ,  C07K2317/55

Abstract: A method for delaying onset of insulin dependent diabetes mellitus (IDDM) in an individual predisposed to developing the disease is disclosed. The method comprises administering a composition comprising an immunologically effective monoclonal antibody or fragment thereof against glutamic acid decarboxylase (GAD) coupled to a nonimmunogenic hydrophilic polymer that provides a hydration shell around the monoclonal antibody for inhibiting immune recognition thereof. Poly(ethylene glycol) is a preferred polymer. A method of reducing insulitis in an IDDM patient and a composition therefor are also described.

Abstract translation: 公开了一种在发生该疾病的个体中延缓胰岛素依赖性糖尿病（IDDM）发病的方法。 该方法包括施用包含免疫有效的单克隆抗体或其片段的组合物，其抗体与非免疫原性亲水性聚合物偶联的谷氨酸脱羧酶（GAD），所述非免疫原性亲水性聚合物在单克隆抗体周围提供水合壳以抑制其免疫识别。 聚（乙二醇）是优选的聚合物。 还描述了减少IDDM患者的胰岛炎的方法及其组合物。

公开(公告)号：US5679559A

公开(公告)日：1997-10-21

申请号：US675120

申请日：1996-07-03

Applicant: Jin-Seok Kim ,  Atsushi Maruyama ,  Toshihiro Akaike ,  Sung Wan Kim

Inventor： Jin-Seok Kim ,  Atsushi Maruyama ,  Toshihiro Akaike ,  Sung Wan Kim

IPC: C12N15/09 ,  A61K38/00 ,  A61K47/48 ,  C08L89/00 ,  C12N15/113 ,  C12N15/64 ,  C12N15/87 ,  C12N15/88

CPC classification number: C12N15/1135 ,  A61K47/48315 ,  A61K47/48838 ,  C12N15/87 ,  A61K38/00 ,  C12N2310/3513 ,  Y10T428/2984

Abstract: A composition for delivery of a selected nucleic acid into a targeted host cell comprises a complex of a hydrophobized, positively charged, biocompatible polymer; a lipoprotein; and a selected nucleic acid. Hydrophobic and electrostatic interactions between the components provide for the formation of the condensed DNA-containing complex. Preferred embodiments of the complex have a slightly positive surface charge and an average diameter of about 200 nm. Plasmids and oligonucleotides can be efficiently delivered with such compositions. A method of delivering a selected nucleic acid to a host cell is also disclosed.

Abstract translation: 用于将选择的核酸递送至靶宿主细胞的组合物包含疏水化，带正电荷的生物相容性聚合物的复合物; 脂蛋白 和选择的核酸。 组分之间的疏水和静电相互作用提供了形成含缩合DNA的复合物。 络合物的优选实施方案具有略微正的表面电荷和约200nm的平均直径。 可以用这样的组合物有效地递送质粒和寡核苷酸。 还公开了将选择的核酸递送至宿主细胞的方法。

公开(公告)号：US12079843B2

公开(公告)日：2024-09-03

申请号：US17684649

申请日：2022-03-02

Applicant: Sung Wan Kim

Inventor： Sung Wan Kim

IPC: G06Q30/02 ,  G06Q30/0241 ,  G06Q30/0251 ,  G06Q30/0272 ,  G06Q30/0273

CPC classification number: G06Q30/0277 ,  G06Q30/0255 ,  G06Q30/0272 ,  G06Q30/0273 ,  G06Q30/0275

Abstract: Disclosed is an on-line advertisement method using an advertisement website. An on-line advertisement method according to an embodiment of the present invention provides an advertisement available to a user terminal at a current position of a user terminal which accesses an advertisement website.

公开(公告)号：US08241198B2

公开(公告)日：2012-08-14

申请号：US12513310

申请日：2007-11-05

Applicant: David A. Bull ,  Rafe C. Connors ,  Harold M. Erickson ,  James Yockman ,  Sung Wan Kim

Inventor： David A. Bull ,  Rafe C. Connors ,  Harold M. Erickson ,  James Yockman ,  Sung Wan Kim

IPC: A61M1/12

CPC classification number: A61K35/34 ,  A61B8/12 ,  A61M1/1001 ,  A61M1/1006 ,  A61M1/1008 ,  A61M1/12 ,  A61M1/122 ,  A61M1/127 ,  A61M1/3472 ,  A61M1/3618 ,  A61M1/3621 ,  A61M1/3667 ,  A61M1/3689 ,  C12N5/0662

Abstract: A biologic ventricular assist device that also has the capability to capture, grow, and administer stem cells to regenerate and restore damaged myocardium in the heart. The device works in conjunction with a traditional ventricular assist device and possesses an additional external path or tube that is in-line with the path of the ventricular assist device. The external path allows for the administration of stem cells, genes, genetically modified cells or other therapeutic biologic or pharmacologic agents, as well as leading to a stem cell collecting accessory (14) that captures circulating stem cells. The stem cell collecting accessory is also associated with a chamber (39) for culturing the captured stem cells. The cultured stem cells can be delivered back to the heart by an electro-mechanical or ultrasound/echocardiographic delivery system that runs through the external path back into the ventricular assist device and allows for the delivery of the stem cells, or other therapeutic biologic or pharmacologic agents, directly into the internal chambers of the heart. Administering the stem cells, genes, genetically modified cells or other therapeutic biologic or pharmacologic agents, either alone or in combination, to the heart allows the myocardium to regenerate and repair itself even while the heart is attached to the ventricular assist device, ultimately allowing the heart to regenerate, recover and allow the VAD to be removed.

Abstract translation: 一种生物心室辅助装置，其还具有捕获，生长和施用干细胞以再生和恢复心脏中损伤的心肌的能力。 该装置与传统的心室辅助装置一起工作，并且具有与心室辅助装置的路径一致的额外的外部路径或管。 外部途径允许施用干细胞，基因，遗传修饰的细胞或其他治疗生物或药理学试剂，以及导致捕获循环干细胞的干细胞收集附件（14）。 干细胞收集附件还与用于培养所捕获的干细胞的室（39）相关联。 培养的干细胞可以通过机电或超声/超声心动图输送系统递送回心脏，该系统通过外部路径返回到心室辅助装置，并允许输送干细胞或其他治疗性生物学或药理学 代理人，直接进入内心的内心。 将心脏单独或组合的干细胞，基因，遗传修饰的细胞或其他治疗性生物或药理学剂施用于心脏，即使在心脏附着于心室辅助装置时也能使心肌再生和修复自身，最终允许 心脏再生，恢复并允许VAD被去除。

公开(公告)号：US08153155B2

公开(公告)日：2012-04-10

申请号：US12496568

申请日：2009-07-01

Applicant: Sun Hwa Kim ,  Ji Hoon Jeong ,  Tae-il Kim ,  Sung Wan Kim ,  David A. Bull

Inventor： Sun Hwa Kim ,  Ji Hoon Jeong ,  Tae-il Kim ,  Sung Wan Kim ,  David A. Bull

IPC: A61K9/14 ,  C07H21/04

CPC classification number: A61K9/5146 ,  A61K47/34 ,  A61K47/59 ,  A61K47/595 ,  A61K47/6455 ,  A61K48/0041 ,  C12N15/111 ,  C12N2320/32

Abstract: An arginine-grafted bioreducible poly(disulfide amine) (“ABP”) as a reagent for efficient and nontoxic gene delivery is described. ABP forms positively charged nano-particles of less than 200 nm with siRNA. ABP is biodegraded under reducing conditions, such as in the cytoplasm. ABP exhibits much higher transfection efficiency than polyethyleneimine in mammalian cells and exhibits no cytotoxicity. ABP is an effective delivery vehicle for gene silencing with siRNA and may be used for treating cancer.

Abstract translation: 描述了精氨酸接枝的可生物还原的聚（二硫化胺）（“ABP”）作为有效和无毒的基因递送的试剂。 ABP用siRNA形成小于200nm的带正电荷的纳米颗粒。 ABP在还原条件下如细胞质中生物降解。 与哺乳动物细胞中的聚乙烯亚胺相比，ABP的转染效率高得多，不显示细胞毒性。 ABP是用于siRNA基因沉默的有效递送载体，可用于治疗癌症。

公开(公告)号：US08058256B2

公开(公告)日：2011-11-15

申请号：US12691566

申请日：2010-01-21

Applicant: Won Jong Kim ,  Sung Wan Kim

Inventor： Won Jong Kim ,  Sung Wan Kim

IPC: A61K48/00 ,  A61K38/04 ,  A61K51/00 ,  C07K5/00

CPC classification number: C12N15/87

Abstract: A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed.

Abstract translation: 将小干扰RNA（siRNA）递送到细胞中的载体包括共价键合到寡精氨酸的胆固醇残基。 将siRNA与载体混合产生含有复合物的组合物。 将细胞与含有复合物的组合物接触导致siRNA递送到细胞中。 靶向血管内皮生长因子的siRNA的递送是癌症的治疗。 还公开了制备载体和复合物的方法。

公开(公告)号：US20110015257A1

公开(公告)日：2011-01-20

申请号：US12649141

申请日：2009-12-29

Applicant: Minhyung Lee ,  Sung Wan Kim

Inventor： Minhyung Lee ,  Sung Wan Kim

IPC: A61K31/711 ,  A61P9/10

CPC classification number: C07K14/52 ,  A61K48/0058 ,  C12N15/85 ,  C12N2830/002

Abstract: Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable carriers. Methods for treating ischemic disease include administering such pharmaceutical compositions to a person in need of such treatment.

Abstract translation: 描述了可用于治疗缺血性疾病如缺血性心脏病的质粒。 质粒在缺氧条件下上调的启动子（RTP801）的控制下表达血管内皮生长因子（VEGF）。 用于治疗缺血性疾病的药物组合物包括缺氧调节的VEGF质粒和药学上可接受的载体的混合物。 用于治疗缺血性疾病的方法包括将这种药物组合物给予需要这种治疗的人。